Physician profile
Amanda M Ray
NPI 1831652080
$4,074.33
in general payments reported to CMS, 2019-2025
22 companies · $950 in 2025
The $950 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $674 · 2022: $1,436 · 2023: $488 · 2024: $527 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $484.63 | 2021-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Abbvie INC. | $480.58 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $368.43 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $345.59 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $281.89 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $261.64 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $243.43 | 2022-2025 | Ingrezza |
| Indivior INC. | $236.90 | 2021-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $227.49 | 2025 | Cobenfy |
| Lundbeck LLC | $198.42 | 2021-2024 | Abilify Asimtufii, Rexulti |
| Corium, LLC | $190.24 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $181.53 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Bausch Health US, LLC | $95.84 | 2021-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $94.76 | 2022-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.20 | 2022-2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $69.68 | 2022-2025 | Qelbree |
| Tris Pharma INC | $66.39 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $40.30 | 2025 | Auvelity |
| Almatica Pharma LLC | $36.76 | 2022 | |
| Adlon Therapeutics L.P. | $36.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.85 | 2022 | |
| Noven Therapeutics, LLC | $18.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.